2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Рекомендации ESC/EAS 2019 года по ведению пациентов с дислипидемиями: модификация липидов для снижения сердечно-сосудистого риска
2019-08-31
SCID: 54.1/b32rpmmp
Discuss with AI
ESC/EAS Guidelinescardiovascular risk reductiondyslipidaemia managementlipid modificationpreventive strategies
Figures from the paper
Abstract (AI)
European guidelines
Key Findings
1
Healthcare professionals should reconcile the guidelines with updated official public-health recommendations and applicable drug and medical-device regulations.
2
The 2019 ESC/EAS Guidelines address lipid modification strategies intended to reduce cardiovascular risk.
3
The guidelines are based on the scientific and medical evidence available at the time of publication.
4
The recommendations support clinical decision-making for preventive, diagnostic, and therapeutic management of dyslipidaemias, while preserving individualized professional judgment.
Research Object
Management of dyslipidaemias (lipid modification interventions to reduce cardiovascular risk)
Research Subject
lipid modification strategies to reduce cardiovascular risk
Publication Details
Publication Date
2019-08-31
Journal
Publisher
ISSN
Cited by
9421
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai13
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease2017
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease2017
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes2015
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20162018
ESC/EAS Guidelines for the management of dyslipidaemias2011
Statins for the primary prevention of cardiovascular disease2013
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction2002
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials2009
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease2018
Cited by19
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
2021 ESC/EACTS Guidelines for the management of valvular heart disease2021
2023 ESC Guidelines for the management of acute coronary syndromes2023
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
2020 International Society of Hypertension Global Hypertension Practice Guidelines2020
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease2020
Arterial hypertension in adults. Clinical guidelines 20202020
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease2019
2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines2022
Ten things to know about ten cardiovascular disease risk factors – 20222022
Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: A Cohort Study2024
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk2022
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention2025
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study2024
Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry2025
Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US2024
Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France2025